See how Viracor's comprehensive, noninvasive solutions for assessing subclinical and acute rejection, infection and toxicity could benefit your transplant program.
Introducing a donor-derived cell-free DNA assay that utilizes a liquid biopsy and provides healthcare professionals with actionable data — comparable to other dd- cfDNA assays on the market — for diagnosing and monitoring rejection in kidney transplant patients.
30876 Viracor TRAC™ Kidney
When rejection is not the underlying cause of symptoms, could it be an active BKV or other infection? Infectious disease investigative testing can be critical for treatment management.
Immunosuppressive drugs are essential to prevent rejection, but the risk of toxicity varies due to an individual patient's metabolism, absorption and drug interactions. Additionally, variability is observed in the pharmacokinetics of triazole antifungal drugs. By using drug level monitoring with timely results, the physician is able to individualize drug dosage to improve efficacy and reduce toxicity.
Immunological rejection presents one of the main obstacles to the long-term success of organ transplantation. Accurate, noninvasive laboratory assays are emerging as an alternative to biopsies for diagnosis of rejection. One of the most promising assays makes use of the proportion of donor-derived cell-free DNA (dd-cfDNA) as an indicator of organ damage, primarily due to rejection but also potentially due to infection or drug toxicity. Reviewing data published to date demonstrates that measurement of dd-cfDNA has broad clinical utility as a rejection biomarker.
With over 30 years of specialized expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients, Viracor is committed to helping medical professionals, transplant teams and reference labs get results faster, when it matters most.
We would be honored to be your diagnostic testing partner. For more information and to set up an account, please click on the button below.
Connect with us